Cizolirtine Citrate, an Effective Treatment for Symptomatic Patients with Urinary Incontinence Secondary to Overactive Bladder: A Pilot Dose-Finding Study

Martínez‐García, Roberto; Abadias, M.; Arañó, Pedro; Perales, L; Ruiz, José Luis Martínez; Sust, Mariano; Conejero, J

doi:10.1016/j.eururo.2008.04.027

Cited by 18 publications

(7 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Further, cizolirtine citrate resulted in improvement in urinary incontinence and urgency in symptomatic outpatients with OAB and/or urodynamic diagnosis of detrusor overactivity (Martinez-Garcia et al, 2008). Therefore, it is possible that increased expression of CGRP- or SP-IR in bladder afferent cells and central and peripheral projections could contribute to this hyperreflexia.…”

Section: 3 Tachykinins and Calcitonin-gene Related Peptide (Cgrp) mentioning

confidence: 99%

Neuropeptides in Lower Urinary Tract Function

Arms

Vizzard

2011

Urinary Tract

View full text Add to dashboard Cite

Numerous neuropeptide/receptor systems including vasoactive intestinal polypeptide, pituitary adenylate cyclase-activating polypeptide, calcitonin gene-related peptide, substance P, neurokinin A, bradykinin, and endothelin-1 are expressed in the lower urinary tract (LUT) in both neural and non-neural (e.g., urothelium) components. LUT neuropeptide immunoreactivity is present in afferent and autonomic efferent neurons innervating the bladder and urethra and in the urothelium of the urinary bladder. Neuropeptides have tissue-specific distributions and functions in the LUT and exhibit neuroplastic changes in expression and function with LUT dysfunction following neural injury, inflammation and disease. LUT dysfunction with abnormal voiding including urinary urgency, increased voiding frequency, nocturia, urinary incontinence and pain may reflect a change in the balance of neuropeptides in bladder reflex pathways. LUT neuropeptide/receptor systems may represent potential targets for therapeutic intervention.

show abstract

Section: 3 Tachykinins and Calcitonin-gene Related Peptide (Cgrp) mentioning

confidence: 99%

Neuropeptides in Lower Urinary Tract Function

Arms

Vizzard

2011

Urinary Tract

View full text Add to dashboard Cite

show abstract

“…). The full texts of 119 trials were reviewed, and 38 were ultimately included in the analysis . Of the 39 potentially relevant trials additionally identified from http://ClinicalTrials.gov, three were included in the analysis .…”

Section: Resultsmentioning

confidence: 99%

Potential Primary Endpoint for Exploratory Clinical Trial in Patients with Overactive Bladder: A Systematic Literature Review

Iino

Kaneko

Narukawa

2016

LUTS

View full text Add to dashboard Cite

show abstract

“…Cizolirtine citrate is a substance P and calcitonin gene-related peptide release modulator that is being evaluated in the treatment of OAB in humans [78,79]. Preliminary findings look promising, with results similar to those for oxybutynin during a randomized trial [79].…”

Section: Current Overactive Bladder Treatmentsmentioning

confidence: 88%

The Overactive Bladder: New Concepts of Etiology and Treatment

Lee

Goldman

2010

Curr Bladder Dysfunct Rep

View full text Add to dashboard Cite

Overactive bladder (OAB) is a disorder characterized by urinary urgency. In the past, the pathophysiology and treatment of OAB focused on the parasympathetic efferent innervation of detrusor smooth muscle cells. However, recent evidence has provided a clearer understanding of the neurological, chemical, and functional physiology of the bladder and how it relates to the pathophysiology of OAB. Urothelial cells, sensory neurons, and interstitial cells of Cajal have secretory and receptor functions that play an important role in bladder function and dysfunction. As we learn more about bladder function and the mechanism of current OAB treatments, newer forms of therapy are emerging. These include neuromodulation, botulinum toxin, and the development of new drugs based on the pathophysiology of OAB.

show abstract

Cizolirtine Citrate, an Effective Treatment for Symptomatic Patients with Urinary Incontinence Secondary to Overactive Bladder: A Pilot Dose-Finding Study

Cited by 18 publications

References 26 publications

Neuropeptides in Lower Urinary Tract Function

Neuropeptides in Lower Urinary Tract Function

Potential Primary Endpoint for Exploratory Clinical Trial in Patients with Overactive Bladder: A Systematic Literature Review

The Overactive Bladder: New Concepts of Etiology and Treatment

Contact Info

Product

Resources

About